Uncategorized Archives - Page 4 of 86 - PsychedelicNewsWire (PNW)

ThursdayJan 26, 2023 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Update on UCSF Psylocibin Clinical Trial

SILO recently provided status update on its sponsored clinical trial with UCSF examining psilocybin’s effects on inflammation Targeted patient populations from study may provide support for development and use of psilocybin as a therapeutic to treat inflammatory conditions Data collection from all study groups expected by April 2023 SILO additionally evaluating its ketamine formulation through its partnership agreement with Zylö Therapeutics Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company that fuses traditional medicine with psychedelics, recently provided a progress update on its sponsored clinical trial with the University of California, San Francisco (“UCSF”) examining the effect of psilocybin on…

ThursdayJan 12, 2023 9:00 am

Silo Pharma Inc. (NASDAQ: SILO) Provides Positive Update on Ongoing Study into the Use of Joint Homing Peptides as an Alternative Treatment for Rheumatoid Arthritis

Silo Pharma recently provided an update on an ongoing study delving into the potential use of SPU-21 joint homing peptides as an alternative treatment for rheumatoid arthritis The study, which is being carried out in conjunction with the University of Maryland, Baltimore, has resulted in positive initial results Since its founding, Silo Pharma has rapidly gained a reputation for its innovative approach towards seeking solutions to address a variety of underserved medical conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused around merging traditional therapeutics with psychedelic research, recently revealed the positive interim data from its dose optimization…

ThursdayDec 01, 2022 3:00 pm

Enrich Your Psychedelic Trip by Listening to These Artists

If you have been paying attention to the internet and the mainstream media for the past couple of years, you probably noticed that psychedelics are all the rage these days. Even though psychedelics are rigidly controlled at the federal level, initial research indicates that they have the potential to alleviate a variety of mental health conditions with relatively few side effects. As a result, millions of dollars have been invested into psychedelic research, and more people are looking to consume hallucinogenic drugs for health, wellness and spiritual purposes. Survey data shows that around 8% of young American adults reported using…

WednesdayNov 16, 2022 3:32 pm

Psychedelics Stocks Jump as Colorado Voters Approve Initiative

With the midterms steadily drawing to a close, it is becoming clear that Americans were largely in support of drug reform. In Colorado, voters approved a ballot measure that would allow the purchase, possession and use of specific psychedelic fungi and plants. The measure will legalize the cultivation, possession, sharing and use of ibogaine, psilocybin, mescaline, psilocin and DMT for adults aged 21 and older. Soon after news of the legislation’s approval was announced, psychedelic stock prices began trending upward. Under the new measure, Colorado would have to formulate new regulations to govern the distribution and administration of the aforementioned…

ThursdayNov 10, 2022 10:42 am

Frustrated with VA, US Veterans Go Overseas for Psychedelic Treatment

In recent years, emerging studies involving psychedelics have found that hallucinogenic drugs can be effective at treating a variety of mental health conditions. These clinical trials and studies have revealed that when paired with psychotherapy, psychedelics can result in positive and profound long-term outcomes for patients suffering from conditions such as depression and post-traumatic stress disorder (PTSD). Coincidentally, these mental health issues have plagued military veterans for decades and resulted in the deaths of countless vets. Some studies show that around 14% to 16% of Iraq and Afghanistan war veterans suffer from depression or PTSD. Although psychedelics could be used…

MondayNov 07, 2022 10:52 am

New Psychedelic Journal to Focus on Publishing Psychedelic Research

The psychedelic medicine field is growing rapidly, as centers devoted to the study of psychedelic drugs continue to expand across Europe and North America. A new peer-reviewed journal, “Psychedelic Medicine,” will focus on publishing articles on the status of investigational psychedelic drugs in clinical trials and advances made in psychedelic research. The journal’s editorial board members agreed that the board would mainly center on serotonergic agonists and proposed that the term “psychedelic” be used in a broader sense scientifically. At the moment, the term “psychedelic” is normally used to describe psychoactive drugs that possess a primary mechanism of action which…

FridayNov 04, 2022 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Extends Columbia University Agreement to Continue Research for Therapeutics to Treat Alzheimer’s Disease

Silo recently extended Columbia University agreement to continue research for novel therapeutics to treat Alzheimer’s disease and stress-induced anxiety disorder Preclinical studies demonstrate Silo’s jointly-developed Z-pod(TM) delivery technology holds and distributes therapeutics in a time-released manner to potentially provide targeted delivery Additional treatment research includes funding for the UCSF Translational Psychedelic Program to study effects of psilocybin on various inflammatory conditions Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company, fuses traditional therapeutics with psychedelic medicine to treat numerous underserved conditions, including fibromyalgia, post-traumatic stress disorder, and Alzheimer’s disease. Through a joint partnership agreement with Columbia University, researchers are currently…

TuesdayOct 25, 2022 12:39 pm

Survey Finds No Link Between Psychedelics Use, Cancer Risk

New research has found that the use of psychedelic substances is not linked to the lifetime development of cancer. The investigators’ objective was focused on determining whether there was any truth to research from the 1960s that associated the use of psychedelics to a heightened risk of developing cancer. The research in question was conducted in 1967, with those involved reporting that the use of LSD caused chromosomal damage in white blood cells. Subsequent studies also suggested that exposure to LSD could have carcinogenic potential. For their study, the researchers focused on expanding on a 2021 study that explored the…

MondayOct 24, 2022 10:30 am

Silo Pharma Inc.’s (NASDAQ: SILO) Novel Ketamine Formulation Undergoing Safety Evaluation, Pursuing Regulatory Pathway

Ketamine used for decades in large doses for surgical anesthesia, low-dose treatments currently prescribed for pain relief, sedation, and treatment-resistant depression Silo’s time-released ketamine formulation SP-26 currently undergoing safety evaluation, study to uncover maximum tolerated dosing data for future trials SP-26 previously reported positive results in reducing neuropathic nerve pain Silo preparing FDA Pre-Investigational New Drug (“IND”) package for SP-26, intends to pursue 505(b)(2) regulatory pathway Ketamine was approved in the United States in 1970 and has been used extensively for surgical anesthesia. Since then, use of the drug in small doses has expanded considerably to treat pain and treatment-resistant…

WednesdayOct 19, 2022 11:28 am

Study Finds That MDMA May Be Useful in Treating Eating Disorders

An eating disorder is a severe mental health condition that may have damaging emotional and physical consequences for the sufferer. Common eating disorders include bulimia nervosa, binge-eating disorder, and anorexia nervosa. New research has found that MDMA-assisted therapy decreased symptoms of eating disorders in adults suffering from severe PTSD. MDMA, which is commonly known as ecstasy, has demonstrated promise in the treatment of a range of mental health conditions, especially when administered in combination with other therapeutic interventions. The FDA recently granted breakthrough therapy designation for MDMA-assisted therapy for post-traumatic stress disorder, recognizing that it had shown significant improvement over…

News and publishing service for psychedelic related companies

Contact us: 512.354.7000

Category: Uncategorized